Risk factor profile and achievement of treatment goals among hypertensive patients from the Israeli Blood Pressure Control (IBPC) program - initial cost utility analysis

References

• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199–206.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–72.
   PubMed Web of Science ®Google Scholar
• Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–98.
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on preven-tion, detection, evaluation, and treatment of high blood pressure. NIH Publication no. 98–4080 November 1997.
   Google Scholar
• Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105: 152–6.
   Google Scholar
• The Israeli recommendations for treatment and prevention of ischemic heart disease and atherosclerotic vascular disease. Harefuah 2000; 130: 1.
   Google Scholar
• American Diabetes Association: clinical practice recom-mendations. Diabetes Care 2002; 25: S1–147.
   PubMedGoogle Scholar
• Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replace-ment Study (HERS). The HERS Research Group. JAMA 1997; 277: 1281–6.
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67.
   PubMed Web of Science ®Google Scholar
• Lai LL, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment prac-tices in an HMO primary care setting. South Med J 2000; 93: 283–6.
   Google Scholar
• Gerber J. Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia inpatients with coronary artery disease. Am J Cardiol 1997; 80: 57–61H.
   Google Scholar
• EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–82.
   Google Scholar
• Clinical reality of coronary prevention guidelines: a com-parison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
   Google Scholar
• Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001; 19: S33–40.
   Google Scholar
• Menard J, Comu P, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992; 6: 447–58.
   PubMed Web of Science ®Google Scholar
• Elliott WJ. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeco-nomics? Postgrad Med 1996; 99: 251–2.
   Google Scholar
• Pardell H, Tresserras R, Armario P, Hernandez del Rey R. Pharmacoeconomic considerations in the management of hypertension. Drugs 2000; 59: 13–20.
   Google Scholar
• Bernard DB, Townsend RR, Sylvestri MF. Health and disease management: what is it and where is it going? What is the role of health and disease management in hyperten-sion? Am J Hypertens 1998; 11: 103–85.
   Google Scholar
• Goldman S, Fink R, Adler B, Kahan S, Kark JD The Jerusalem Registry of Myocardial Infarction: Incidence and Mortality, 1995. Israel Center for Disease Control, 1998 (in Hebrew).
   Google Scholar
• Central Bureau of Statistics. Diagnostic Statistics of Hos-pitalizations 1990, CBS No 1058, Jerusalem 1997.
   Google Scholar
• Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346: 1468–74.
   Google Scholar
• Bursztyn M, Shpilberg 0, Ginsberg GM, Cohen A, Stess-man J. Hypertension in the Jerusalem 70 year olds study population: prevalence, awareness, treatment and control. Isr J Med Sci 1996; 32: 629–33.
   PubMedGoogle Scholar
• Hammerman-Rozenberg R, Cohen A, Ginsberg G, Maaravi Y, Ebstein RP, Stessman J. Laboratory reference values for the 70 year olds. Isr J Med Sci 1996; 32: 611–20.
   PubMedGoogle Scholar
• Ministry of Health Health in Israel Selected data 2001. Jerusalem, September 2001.
   Google Scholar
• Central Bureau of Statistics. Statistical Abstract of Israel No. 522001; CBS Jerusalem 2001.
   Google Scholar
• Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–72.
   PubMed Web of Science ®Google Scholar
• Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–98.
   PubMed Web of Science ®Google Scholar
• Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocar-dial infarction. Am J Cardiol 1991; 67: 1084–9.
   PubMed Web of Science ®Google Scholar
• Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999; 30: 338–49.
   PubMed Web of Science ®Google Scholar
• Department of Health. The health of the nation: a strategy for health in England. London: HMSO, 1992.
   Google Scholar
• General Medical Services Committee. The new health promotion package. London: British Medical Association, 1993.
   Google Scholar
• Fullard E, Fowler G, Gray M. Promoting prevention in primary care: controlled trial of low technology, low cost approach. Br Med J 1987; 294: 1080–2.
   Google Scholar
• Berglund G, Eriksson KF, Israelsson B, et al. Cardiovascular risk groups and mortality in an urban Swedish male popu-lation: the Malmo Preventive Project. J Intern Med 1996; 239: 489–97.
   PubMed Web of Science ®Google Scholar
• Garber AM, Sox HC Jr, Littenberg B. Screening asympto-matic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med 1989; 110: 622–39.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Lee TT. What a physician needs to know about cost-effectiveness. Cardiol Rev 2000; 8: 96–102.
   PubMedGoogle Scholar
• Ambrosioni E. Healthcare benefits of very-low-dose combi-nation treatment used in the management of hypertension. J Hypertens 2001; 19: S29–36.
   PubMed Web of Science ®Google Scholar
• Pardell H, Tresserras R, Armario P, Hernandez del Rey R. Pharmacoeconomic considerations in the management of hypertension. Drugs 2000; 59: 13–20.
   Google Scholar
• Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6: 417–20.
   PubMed Web of Science ®Google Scholar
• Everitt B Cambridge dictionary of statistics in medical sciences. Cambridge: Cambridge University Press, 1995.
   Google Scholar